ReviewClinical microbiology reviews2012
Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines.
Review in Clinical microbiology reviews, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 1 synthesis or guideline pooled it, 204 citations in OpenAlex.
- Pooled it
- Safety and immunogenicity of a 15-valent pneumococcal conjugate vaccine in Japanese healthy infants: A Phase I study (V114-028).Human vaccines & immunotherapeutics · 2023Trial
- Trial
- Applications of nuclear magnetic resonance spectroscopy in pediatric clinical metabolomics: From research to future perspectives.Journal of food and drug analysis · 2026Review
- Trends and determinants of pneumococcal vaccine uptake among U.S. adults, 2019-2024: a pooled cross-sectional analysis.BMC public health · 2026Article
- Analytical Characterization of Pneumococcal Vaccine Conjugates Using SEC-MALS Technique.Methods and protocols · 2026Article
- Evolution and rise of antimicrobial resistance in key public health bacteria within and across the One Health sectors.Future microbiology · 2026Review
- Article
- Article
- Impact of sequential pediatric pneumococcal conjugate vaccination (PCV10/PCV13/PCV10) on serotype distribution and antimicrobial resistance in invasive and non-invasiveFrontiers in microbiology · 2026Article
- Global Assessment of Health Utilities Associated with Pneumococcal Disease in Children-Targeted Literature Reviews.PharmacoEconomics · 2025Review
- Article
- Update on the evolving landscape of pneumococcal capsule types: new discoveries and way forward.Clinical microbiology reviews · 2025Review
- Pediatric Pleural Effusion and Pneumococcal Vaccination Trends in the Pre- and Post-COVID Era: A Single-Centre Retrospective Study.Children (Basel, Switzerland) · 2025Article
- Article
- Understanding healthcare providers' preferred attributes of pediatric pneumococcal conjugate vaccines in the United States.Human vaccines & immunotherapeutics · 2024Article
- State of pneumococcal vaccine immunity.Human vaccines & immunotherapeutics · 2024Article
- Incidence of pneumococcal disease in children in Germany, 2014-2019: a retrospective cohort study.BMC pediatrics · 2024Article
- Chemical Synthesis of Truncated Capsular Oligosaccharide of Serotypes 6C and 6D ofACS infectious diseases · 2024Article
- Case Report: Hypocomplementemic urticarial vasculitis syndrome in a pediatric patient with complement factor 1 deficiency.Frontiers in pediatrics · 2024Article
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive infections caused by Streptococcus pneumoniae continue to be a major cause of morbidity and mortality worldwide, especially in children under 5 years of age. In the United States, 90% of invasive pneumococcal infections in children are caused by 13 serotypes of S. pneumoniae. The licensure (in 2000) and subsequent widespread use of a heptavalent pneumococcal conjugate vaccine (PCV7) have had a significant impact on decreasing the incidence of serious invasive pneumococcal disease (IPD) in all age groups, especially in children under 2 years of age. However, the emergence of replacement non-PCV7 serotypes, especially serotype 19A, has resulted in an increase in the incidence of serious and invasive infections. In 2010, a 13-valent PCV was licensed in the United States. However, the impact that this vaccine will have on IPD remains to be seen. The objectives of this review are to discuss the epidemiology of serious and invasive pneumococcal infections in the United States in the PCV era and to review some of the pneumococcal vaccines that are in development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.